Beyne Pascale, Bouvier Erik, Werner Patrick, Bourgoin Pierre, Logeart Damien, Alliot Laurent, Daïkha Habiba, Vidaud Michel
Service de Biochimie, AP-HP Hôpital Beaujon, Clichy, France.
Clin Chem Lab Med. 2004 May;42(5):556-9. doi: 10.1515/CCLM.2004.094.
The aim of this study was to define the use of a new cardiac troponin I (cTnI) assay for emergency patients with chest pain and no specific electrocardiographic changes consistent with the presence of ischemia. Patients (n = 106) admitted in Emergency/Cardiology Departments for chest pain and suspicion of acute coronary syndrome (ACS) were randomized into two diagnosis groups (ACS or non-ACS) by two independent cardiologists. cTnI measurements were performed at admission, and 6 hours and 12 hours later with a new generation assay (Access AccuTnI, Beckman Coulter). Using an upper reference limit of 0.04 microg/l, 27 patients had a cTnI elevation not related to the final diagnosis of ischemia; the positive predictive value (PPV) was 67% with specificity 48%. The decisional value was re-defined and set at 0.16 microg/l, a concentration corresponding to the 99th percentile of the non-ACS patient group. Precision (coefficient of variation) was 8% at this level, PPV 97% and specificity 98%. This new decisional value is now used in our institution and could be included in standard care guidelines to improve the management of patients presenting chest pain in emergency departments.
本研究的目的是确定一种新型心肌肌钙蛋白I(cTnI)检测方法在胸痛且无提示缺血的特异性心电图改变的急诊患者中的应用。因胸痛并怀疑急性冠脉综合征(ACS)而入住急诊/心内科的患者(n = 106)由两名独立的心脏病专家随机分为两个诊断组(ACS组或非ACS组)。入院时、6小时后和12小时后使用新一代检测方法(贝克曼库尔特公司的Access AccuTnI)进行cTnI检测。采用0.04μg/l的参考上限,27例患者的cTnI升高与最终缺血诊断无关;阳性预测值(PPV)为67%,特异性为48%。重新定义决策值并设定为0.16μg/l,该浓度对应于非ACS患者组的第99百分位数。在此水平下,精密度(变异系数)为8%,PPV为97%,特异性为98%。这个新的决策值目前已在我们机构使用,并且可纳入标准护理指南,以改善急诊科胸痛患者的管理。